Skip to main navigation
Skip to content
Header Nav
Menu
About Us
Introduction
Senior Management Team
Board of Directors
Scientific Advisory Board
Pipeline
Overview
Rademikibart (CBP-201)
Icanbelimod (CBP-307)
CBP-174
Our Science
Clinical Trials
Investors
Overview
Press Releases
Presentations, Events & News
Stock Information
Corporate Governance
Financials & Filings
Investor Resources
Careers
Contact
Header Nav
Menu
About Us
Introduction
Senior Management Team
Board of Directors
Scientific Advisory Board
Pipeline
Overview
Rademikibart (CBP-201)
Icanbelimod (CBP-307)
CBP-174
Our Science
Clinical Trials
Investors
Overview
Press Releases
Presentations, Events & News
Stock Information
Corporate Governance
Financials & Filings
Investor Resources
Careers
Contact
Event Details
IR Nav
Investor Menu
Overview
Press Releases
Presentations, Events & News
Stock Information
Stock Quote & Chart
Historic Price Lookup
Analyst Coverage
Corporate Governance
Corporate Governance Documents
Board of Directors
Management
Committee Composition
Board Diversity Matrix
Financials & Filings
SEC Filings
Investor Resources
Investor FAQs
Email Alerts
IR Contact
Long-Term Data from Rademikibart Atopic Dermatitis China Pivotal Trial
November 21, 2023
at 8:30 AM EST
Webcast Replay
Supporting Materials
Rademikibart CN002 52-week data in AD
803.9 KB
Toolkit
Print Page
Email Alerts
RSS Feeds
IR Contact
Scroll back to top
